We appreciate the comments from Dr. Cheng-Ruei Yang et al. about our recent article that investigated whether IL17-inhibitors (IL17i) initiation is associated with a higher risk of inflammatory bowel disease (IBD) in patients with psoriasis (PsO), psoriatic arthritis and ankylosing spondylitis (PsA/AS).(1) We demonstrated that treatment with IL17i was not associated with a higher risk of IBD in patients with PsO, or PsA/AS when taking into account the severity of the underlying disease i.e. when using etanercept as a comparator. The main strength of this study was the use of a large sample from a nationally representative database, the French national health data system (Système National des Données de Santé [SNDS]) which has contained comprehensive data on all reimbursements for health-related expenditures, on ambulatory care and hospitalizations since 2006.(2,3)

中文翻译：

---

回复：评论：银屑病、银屑病关节炎和强直性脊柱炎患者启动白细胞介素 17 抑制剂的炎症性肠病风险

感谢Cheng-Ruei Yang 博士等人的评论. 关于我们最近的一篇文章，该文章调查了 IL17 抑制剂 (IL17i) 的启动是否与银屑病 (PsO)、银屑病关节炎和强直性脊柱炎 (PsA/AS) 患者的炎症性肠病 (IBD) 高风险相关。(1) 我们证明当考虑到潜在疾病的严重程度时，即当使用依那西普作为比较时，IL17i 治疗与 PsO 或 PsA/AS 患者的 IBD 风险较高无关。这项研究的主要优势是使用了来自具有全国代表性的数据库的大样本，即法国国家卫生数据系统（Système National des Données de Santé [SNDS]），其中包含有关所有与健康相关的支出报销的综合数据，自 2006 年以来的门诊护理和住院治疗。(2,3)